A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Visudyne in Neovascular Macular Degeneration, sponsored by Bayer. Completed at 62 sites in 8 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 12th largest by enrollment, is one of 12 that started in 2014, is one of 27 in phase 4, and was the 20th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 12 started in 2014.
This study's enrollment of 333 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
30 studies in Macular Degeneration by Bayer: none open now, 1 under way, none of them phase 3. Of 29 finished, 10 (34%) have results posted.
Among the 30 studies in Macular Degeneration by Bayer, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2014, is one of 5 in phase 4, and was the 10th registered.
Bayer’s Macular Degeneration studies by the year they started, since 2008.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Bayer’s 30 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) · Other: Visudyne
Eylea is administered as an intravitreal injection
Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
Time frame: From Baseline to Week 52
Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
Time frame: At Week 52
Percentage of Subjects Who Never Need Rescue Therapy in the First Year
Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.
Time frame: Baseline to Week 52
Number of PDT Treatments in the Study Eye Before Week 52
Time frame: Baseline to Week 52
Number of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 52
Time frame: Baseline to Week 52
Time to First Administration of PDT in the Study Eye Before Week 52
Time frame: Baseline to Week 52
Change of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
Time frame: Baseline to Week 52
Percentage of Subjects Who Gained ≥5, 10, or 15 Letters at Week 52
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
Time frame: Baseline to Week 52
Percentage of Subjects Who Lost ≥5, 10, or 15 Letters at Week 52
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
Time frame: Baseline to Week 52
Percentage of Subjects With Complete Polyp Regression at Week 52
Complete polyp regression was defined as absent or indeterminate visual polyps on Indocyanine green angiography (ICGA) in the study eye.
Time frame: Baseline to Week 52
Change of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52
Leakage is the release of fluorescein dye from diseased retinal vessels. Leakage area is defined as the area showing presence of fluorescein dye in the late stages of fluorescein angiography.
Time frame: Baseline to Week 52
Change of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52
Retinal and lesion characteristics, such as central retinal thickness (CRT), were evaluated by OCT in both eyes at every study visit. CRT was measured using optical coherence tomography to determine the average thickness of the retina in a circle with 1 millimeter of diameter centered on the fovea. This value is reported by some OCT devices as central subfield thickness (CST).
Time frame: Baseline to Week 52
Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 52
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
Time frame: Baseline to Week 52
Percentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 52
Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.
Time frame: Baseline to Week 52
The study was conducted at multiple centers in 8 countries worldwide starting from 29 May 2014 (first subject first visit). Primary completion reached on 12 Aug 2016.
| Milestone | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT | Aflibercept (Non-randomized) |
|---|---|---|---|
| Started | 157 | 161 | 15 |
| Completed | 137 | 147 | 0 |
| Not completed | 20 | 14 | 15 |
| Withdrew: Adverse event | 5 | 4 | 3 |
| Withdrew: Death | 3 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 3 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 7 |
| Withdrew: Other reasons | 5 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
| Letters correctly read | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF) | 10.7 ± 11.3 | 10.8 ± 10.7 |
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
| Percentage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52 | 97.5 | 96.9 |
Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.
| Percentage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Percentage of Subjects Who Never Need Rescue Therapy in the First Year | 87.9 | 85.7 |
| PDT administrations | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Number of PDT Treatments in the Study Eye Before Week 52 | 0.2 ± 0.7 | 0.2 ± 0.4 |
| Aflibercept injections | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Number of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 52 | 5.2 ± 1.1 | 5.1 ± 0.8 |
| Days | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Time to First Administration of PDT in the Study Eye Before Week 52 | 131.2 (80 to 278) | 128.2 (80 to 315) |
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
| Letters | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Change of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye | 10.7 ± 11.3 | 10.8 ± 10.7 |
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
| Percentage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Gained ≥ 5 | 73.9 | 78.9 |
| Gained ≥ 10 | 55.4 | 57.1 |
| Gained ≥ 15 | 33.1 | 36.6 |
Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.
| Percentage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Lost ≥ 5 | 7.0 | 5.6 |
| Lost ≥ 10 | 3.8 | 3.1 |
| Lost ≥ 15 | 2.5 | 3.1 |
Complete polyp regression was defined as absent or indeterminate visual polyps on Indocyanine green angiography (ICGA) in the study eye.
| Percetage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Percentage of Subjects With Complete Polyp Regression at Week 52 | 38.9 | 44.8 |
Leakage is the release of fluorescein dye from diseased retinal vessels. Leakage area is defined as the area showing presence of fluorescein dye in the late stages of fluorescein angiography.
| Square millimeter | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Change of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52 | -1.3 ± 3.6 | -1.2 ± 3.7 |
Retinal and lesion characteristics, such as central retinal thickness (CRT), were evaluated by OCT in both eyes at every study visit. CRT was measured using optical coherence tomography to determine the average thickness of the retina in a circle with 1 millimeter of diameter centered on the fovea. This value is reported by some OCT devices as central subfield thickness (CST).
| Millimeter | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Change of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52 | -137.7 ± 116.0 | -143.5 ± 110.5 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
| Scores on a scale | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 52 | 4.7 ± 10.3 | 7.3 ± 12.5 |
Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.
| Percentage of subjects | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT |
|---|---|---|
| Percentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 52 | 12.1 | 14.3 |
Collected over From start of study treatment up to 30 days after the last treatment. Approximately 100 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept + Sham PDT | 3/157 (1.9%) | 27/157 (17.2%) | 59/157 (37.6%) |
| Aflibercept + Active PDT | 0/161 (0%) | 25/161 (15.5%) | 49/161 (30.4%) |
| Aflibercept (Non-randomized) | 1/15 (6.7%) | 4/15 (26.7%) | 3/15 (20%) |
| Event | Aflibercept + Sham PDT | Aflibercept + Active PDT | Aflibercept (Non-randomized) |
|---|---|---|---|
| Retinal pigment epithelial tearEye disorders | 0/157 | 0/161 | 1/15 |
| Sudden cardiac deathGeneral disorders | 0/157 | 0/161 | 1/15 |
| Acoustic neuromaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/157 | 0/161 | 1/15 |
| Senile dementiaNervous system disorders | 0/157 | 0/161 | 1/15 |
| PneumoniaInfections and infestations | 0/157 | 3/161 | 0/15 |
| ArrhythmiaCardiac disorders | 2/157 | 0/161 | 0/15 |
| CataractEye disorders | 2/157 | 0/161 | 0/15 |
| FallInjury, poisoning and procedural complications | 2/157 | 0/161 | 0/15 |
| Rib fractureInjury, poisoning and procedural complications | 2/157 | 0/161 | 0/15 |
| Visual acuity reducedEye disorders | 0/157 | 2/161 | 0/15 |
| Event | Aflibercept + Sham PDT | Aflibercept + Active PDT | Aflibercept (Non-randomized) |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 25/157 | 18/161 | 0/15 |
| HypertensionVascular disorders | 6/157 | 13/161 | 2/15 |
| Dry eyeEye disorders | 6/157 | 11/161 | 0/15 |
| Ocular hypertensionEye disorders | 3/157 | 1/161 | 1/15 |
| Retinal pigment epithelial tearEye disorders | 4/157 | 0/161 | 1/15 |
| DepressionPsychiatric disorders | 1/157 | 0/161 | 1/15 |
| Conjunctival haemorrhageEye disorders | 10/157 | 5/161 | 0/15 |
| Vitreous floatersEye disorders | 9/157 | 1/161 | 0/15 |
| Visual acuity reducedEye disorders | 7/157 | 9/161 | 0/15 |
| Intraocular pressure increasedInvestigations | 6/157 | 9/161 | 0/15 |
Baseline characteristics is reported in Full analysis set which included all randomized subjects (N=318).
| Age, Continuous(Years) | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT | Total |
|---|---|---|---|
| Mean | 70.8 ± 8.4 | 70.4 ± 8.0 | 70.6 ± 8.2 |
| Sex: Female, Male(Participants) | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT | Total |
|---|---|---|---|
| Female | 47 | 49 | 96 |
| Male | 110 | 112 | 222 |
| Baseline BCVA score(Letters) | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT | Total |
|---|---|---|---|
| Mean | 57.7 ± 11.3 | 59.0 ± 11.5 | 58.4 ± 11.4 |
| Central Subfield Thickness(Micrometer) | Aflibercept + Sham Photodynamic Therapy (PDT) | Aflibercept + Active PDT | Total |
|---|---|---|---|
| Mean | 347.8 ± 118.9 | 346.1 ± 117.5 | 346.9 ± 118.0 |
Ran from May 2014 to primary completion in Aug 2016, 26 months.
Results were first posted in Jan 2019, 2 years 5 months after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 26 months is close to that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept